ICD-10 Code C77.8: Secondary cancer, multiple lymph nodes

Key Takeaways

ICD-10 Code C77.8 describes secondary and unspecified malignant neoplasm of lymph nodes of multiple regions, meaning cancer has spread to lymph nodes across more than one anatomical zone.

C77.8 is a billable, specific ICD-10-CM code valid for FY2026 reimbursement submissions under HIPAA-covered transactions.

Always sequence C77.8 as a secondary code alongside the primary malignancy code; omitting the primary is the most common audit trigger for oncology claims.

Pabau’s claims management software helps oncology billing teams track dual-code sequencing requirements and reduce claim rejections across multi-site practices.

ICD-10 Code C77.8 is a billable diagnosis code for secondary and unspecified malignant neoplasm of lymph nodes of multiple regions—cancer that has spread to lymph nodes across two or more distinct anatomical zones. It is valid for FY2026 reimbursement under HIPAA-covered transactions.

Because C77.8 is a secondary site code, it must always be sequenced alongside the primary malignancy code. This guide covers its definition, code hierarchy, documentation requirements, sibling codes, and ICD-9-CM crosswalk.

ICD-10 Code C77.8: Clinical description

C77.8 applies when a patient’s cancer has spread beyond its original site to lymph nodes in more than one anatomical zone. The code sits under the C76-C80 chapter block in the CDC/NCHS ICD-10-CM classification system, which covers malignant neoplasms of ill-defined, other secondary, and unspecified sites.

The official ICD-10-CM description is: Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions. “Secondary” confirms this is metastatic disease, not a primary lymph node malignancy such as lymphoma.

“Multiple regions” distinguishes it from the six site-specific C77 subcodes (C77.0 through C77.5), each of which captures spread to a single, named anatomical zone. When documentation confirms involvement in two or more distinct regions, C77.8 is the appropriate assignment.

C77.8 is a billable, specific code. It has been valid in every ICD-10-CM fiscal year from FY2016 through FY2026 with no description changes. That stability makes it one of the more straightforward codes in the C77 family to apply, provided the documentation supports the “multiple regions” finding.

C77.8 code hierarchy and parent structure

Understanding where C77.8 sits in the code tree helps coders select the right level of specificity and avoid under-coding. The hierarchy runs as follows:

• Chapter 2: Neoplasms (C00-D49)
• Block C76-C80: Malignant neoplasms of ill-defined, other secondary and unspecified sites
• Category C77: Secondary and unspecified malignant neoplasm of lymph nodes
• Code C77.8: Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions

The parent category C77 itself is not billable; only the subcodes (C77.0 through C77.9) can be submitted on a claim. Category C77 carries a note from the CMS ICD-10-CM Official Guidelines requiring the code to be used with the primary malignancy code when known, which is the dual-coding rule explored in the section below.

Accurate hierarchy navigation matters for oncology practices using patient record software that populates diagnosis fields from ICD-10 lookups. Selecting C77 (the non-billable parent) instead of C77.8 triggers an immediate claim scrubbing rejection.

Coding guidelines and documentation requirements for ICD-10 Code C77.8

The ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.2, set out the sequencing rules that govern all neoplasm codes. For C77.8, three rules carry the most practical weight.

Dual-coding requirement

C77.8 is a secondary site code. When the primary malignancy is known and currently being treated, the primary site code sequences first and C77.8 sequences as an additional diagnosis. For example, a patient with breast cancer (C50.911) who now has lymph node spread across the axilla and inguinal regions would be coded: C50.911 first, then C77.8.

If the primary site has been previously excised and is no longer under active treatment, coders use a personal history code (Z85 series) for the original primary and sequence C77.8 as the principal diagnosis.

Correct sequencing protects medical billing workflows from the audit flags that arise when a secondary code appears without a corresponding primary.

Documentation specificity for “multiple regions”

The documentation must explicitly support multi-region involvement. Pathology reports, imaging findings (PET/CT, CT with contrast), or the attending physician’s note should name at least two distinct anatomical lymph node regions.

Vague language such as “widespread lymphadenopathy” is insufficient on its own. Coders should query the treating clinician if the record does not clearly differentiate between regional and multi-regional spread.

Distinguishing secondary neoplasm from primary lymph node malignancy

C77.8 codes metastatic spread to lymph nodes from a non-lymphatic primary. It does not code lymphoma or other primary lymph node malignancies, which fall under C81-C86, and it does not apply to non-cancerous nodal growths coded as benign neoplasm of lymph nodes (D36.0).

Applying C77.8 to a patient with newly diagnosed diffuse large B-cell lymphoma is a clinical coding error with potential payer audit consequences. The distinction depends on histology and primary site confirmation in the pathology report.

C77 sibling codes and when to use each

Choosing between the C77 subcodes is a daily judgment call for oncology coders. The deciding factor is always the anatomical specificity documented in the record.

C77.8 vs C77.9: The practical distinction is documentation quality. C77.9 applies when the record confirms lymph node involvement but does not specify where. C77.8 requires affirmative documentation of spread across multiple named regions.

If the coder cannot verify the regions from the record, C77.9 is the more defensible assignment while a physician query is pending. Review your patient care management documentation protocols to ensure oncology notes routinely capture anatomical specificity at each imaging review.

Streamline oncology billing with Pabau

Pabau's claims management tools help oncology and specialist practices track dual-code sequencing, reduce claim scrubbing rejections, and maintain audit-ready documentation across every patient encounter.

Book a demo

ICD-9-CM crosswalk and transition context for C77.8

Prior to the October 2015 ICD-10-CM transition, the equivalent classification was ICD-9-CM code 196.8 (Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites). The CMS General Equivalence Mappings (GEMs) file maps 196.8 to C77.8 as the forward translation.

Historical claims data, audits referencing pre-2016 encounters, and legacy EHR migration projects may surface 196.8 in records; coders should substitute C77.8 for any current-year submission.

A key structural improvement in ICD-10-CM is that the C77 family provides greater anatomical granularity than ICD-9-CM’s 196 subcategories, which used a parallel regional structure.

Practices reviewing historical data can use a bulk ICD-9 to ICD-10 crosswalk tool for code conversion, but should always verify mappings against the current-year CMS GEMs file rather than commercial crosswalk tools alone—particularly for cancer codes with staging implications.

For practices managing compliance documentation during legacy data migrations, compliance management features that log code-change audit trails can reduce exposure during payer audits of converted records.

Facilities coding solid-tumor primaries that commonly seed multiple nodal regions may also find the guidance on malignant neoplasm of the thyroid gland (C73) a useful companion reference for sequencing rules in complex multi-diagnosis encounters.

Related secondary malignancy codes and common co-coding scenarios

C77.8 rarely appears alone on a claim. Oncology encounters typically involve the primary malignancy code—for example, malignant neoplasm of the rectum (C20)—and, depending on the stage and treatment phase, one or more additional secondary site codes from the C78-C79 ranges. The following combinations appear regularly in oncology billing.

• C77.8 + C78 series: When cancer has spread to both multiple lymph node regions and secondary respiratory or digestive organs (e.g., lung metastasis coded C78.00), both secondary codes are listed after the primary.
• C77.8 + C79 series: Multi-region lymph node spread alongside secondary bone (C79.51), brain (C79.31), or liver (C78.7) metastasis is common in late-stage solid tumors.
• C77.8 + C80.1: When the primary site is unknown, C80.1 (Malignant (primary) neoplasm, unspecified) sequences first with C77.8 as the secondary code. This combination is appropriate when workup has not identified the primary; it is not a substitute for failing to document a known primary.

Coders working in oncology practices that see high volumes of metastatic disease benefit from HIPAA-compliant clinical software that supports multi-diagnosis claim construction without forcing a single-code workflow.

For practices using AI-assisted documentation, Pabau’s AI medical scribe can help capture the clinical detail needed to distinguish C77.8 from adjacent codes at the point of care.

Because the dual-coding principle applies consistently across ICD-10-CM secondary site codes, coders handling complex oncology cases should confirm anatomical specificity and primary-site sequencing at every encounter before submission.

Conclusion

C77.8 captures one of the most clinically complex scenarios in oncology coding: metastatic disease spanning multiple lymph node regions simultaneously. Getting the code right depends on three things: confirming the documentation explicitly names two or more distinct anatomical regions, sequencing the primary malignancy code first, and distinguishing secondary neoplasm from primary lymph node malignancy in the pathology record.

Practices managing high volumes of oncology and complex multi-diagnosis claims benefit from purpose-built clinical documentation and billing tools. Pabau’s claims management software supports multi-code encounter construction, audit-ready record keeping, and the kind of documentation specificity that keeps C77.8 claims defensible. Book a demo to see how Pabau handles complex oncology billing workflows.

Continue your research

Need a structured approach to oncology patient records? Pabau’s client record management provides audit-ready clinical documentation tools for specialist practices managing complex multi-diagnosis encounters.

Managing compliance documentation across your practice? Pabau’s digital forms let you build structured intake and clinical assessment templates that capture the region-specific detail needed for defensible secondary neoplasm coding.

Frequently asked questions